Literature DB >> 10985791

Identification of the sites of incorporation of [3H]ethidium diazide within the Torpedo nicotinic acetylcholine receptor ion channel.

M B Pratt1, S E Pedersen, J B Cohen.   

Abstract

The binding sites of ethidium, a noncompetitive antagonist of the nicotinic acetylcholine receptor (nAChR), have been localized in the Torpedo nAChR in the desensitized state by use of a photoactivatible derivative, [(3)H]ethidium diazide. At 10 microM [(3)H]ethidium diazide, incorporation into the alpha-, beta-, and delta-subunits was inhibited by the presence of phencyclidine (PCP). Within the alpha-subunit, the incorporation was mapped to a 20-kDa fragment beginning at alphaSer-173 and containing the first three transmembrane segments, alphaM1, alphaM2, and alphaM3. Further digestion of this fragment generated two fragments with PCP-inhibitable incorporation, one containing alphaM1 and one containing both alphaM2 and alphaM3. Within alphaM2, specific incorporation was present in alphaLeu-251 and alphaSer-252, residues that have been previously shown to line the lumen of the ion channel. Digestion of the delta-subunit with S. aureus V8 protease generated a 14-kDa and a 20-kDa fragment, both of which began at Ile-192 and contained PCP-inhibitable labeling. The 14-kDa fragment, containing deltaM1 and deltaM2, was further digested to generate a 3-kDa fragment, containing deltaM2 alone, with PCP-inhibitable incorporation. Digestion of the 20-kDa fragment, which contained deltaM1, deltaM2, and deltaM3, generated two fragments with incorporation, one containing the deltaM1 segment and the other containing deltaM2 and deltaM3. These results establish that in the desensitized state of the nAChR, the high-affinity binding site of ethidium is within the lumen of the ion channel and that the bound drug is in contact with amino acids from both the M1 and M2 hydrophobic segments.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10985791     DOI: 10.1021/bi0011680

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  5 in total

1.  Negative allosteric modulators that target human alpha4beta2 neuronal nicotinic receptors.

Authors:  Brandon J Henderson; Ryan E Pavlovicz; Jerad D Allen; Tatiana F González-Cestari; Crina M Orac; Andrew B Bonnell; Michael X Zhu; R Thomas Boyd; Chenglong Li; Stephen C Bergmeier; Dennis B McKay
Journal:  J Pharmacol Exp Ther       Date:  2010-06-15       Impact factor: 4.030

2.  Tricyclic antidepressants and mecamylamine bind to different sites in the human alpha4beta2 nicotinic receptor ion channel.

Authors:  Hugo R Arias; Avraham Rosenberg; Katarzyna M Targowska-Duda; Dominik Feuerbach; Krzysztof Jozwiak; Ruin Moaddel; Irving W Wainer
Journal:  Int J Biochem Cell Biol       Date:  2010-03-17       Impact factor: 5.085

3.  Interaction of 18-methoxycoronaridine with nicotinic acetylcholine receptors in different conformational states.

Authors:  Hugo R Arias; Avraham Rosenberg; Dominik Feuerbach; Katarzyna M Targowska-Duda; Ryszard Maciejewski; Krzysztof Jozwiak; Ruin Moaddel; Stanley D Glick; Irving W Wainer
Journal:  Biochim Biophys Acta       Date:  2010-03-19

4.  Interaction of benzylidene-anabaseine analogues with agonist and allosteric sites on muscle nicotinic acetylcholine receptors.

Authors:  H R Arias; H Xing; K Macdougall; M P Blanton; F Soti; W R Kem
Journal:  Br J Pharmacol       Date:  2009-03-26       Impact factor: 8.739

5.  Interaction of bupropion with muscle-type nicotinic acetylcholine receptors in different conformational states.

Authors:  Hugo R Arias; Fernanda Gumilar; Avraham Rosenberg; Katarzyna M Targowska-Duda; Dominik Feuerbach; Krzysztof Jozwiak; Ruin Moaddel; Irving W Wainer; Cecilia Bouzat
Journal:  Biochemistry       Date:  2009-06-02       Impact factor: 3.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.